Livongo, which makes a platform to help people manage chronic conditions, raises $350M+ in its IPO, closing up 36% at $38.10 and valued at ~$3.6B
Christina Farr / CNBC :
Context & Ripple Effects
Livongo's debut caps a fast arc from private rounds to the public market: it raised a $105M Series E at an $800M+ valuation just fifteen months ago, then filed IPO paperwork in June disclosing $32.06M in Q1 revenue against a $14.96M net loss. The stock closing up 36% at $38.10 puts it at roughly $3.6B — more than quadruple that private mark on day one.
It lands on the same day Health Catalyst closes up 51%, making July 26 a strong session for health-data and chronic-condition tech listings, and it follows reports that Livongo, One Medical, and Teladoc together drew $1.6B in convertible notes in the past month.
First-order effects
- Livongo banks over $350M of new cash and gains public equity as acquisition currency, while its Series E investors see their stakes marked above 4x in a single day.
- The pop validates the connected-device-plus-software model despite ongoing losses — the market is pricing growth in chronic-condition monitoring, not current profitability.
Second-order effects
- Teladoc, already sharing the convertible-note window with Livongo, gains a clearly priced public target in adjacent virtual care — groundwork for what becomes its $18.5B buyout of Livongo a year later.
- Rivals in telehealth-based diabetes management get a valuation benchmark to raise against, as Virta Health's subsequent round at roughly $1.1B shows private capital repricing the category upward.
Third-order effects
- If the pattern holds — big first-day pops for digital-health platforms followed by consolidation — chronic-care management shifts from a startup category into a roll-up arena dominated by listed acquirers like Teladoc.
- The playbook proves durable enough that Omada Health can still take a virtual chronic-care company public six years later, suggesting investor appetite for the model outlasts any single market cycle.
The trend: Virtual chronic-care platforms are cycling from venture funding through hot IPOs into consolidation by larger telehealth acquirers, with each public debut resetting valuations for the whole category.